Loading
Life sciences · Phase EARLY_PHASE1 Trial
ClinicalTrials.gov · October 9, 2026
No summary has been generated for this record yet. What follows is drawn from its source metadata only.
Phase EARLY_PHASE1 Trial.
No findings were extractable from the material analysed.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This record has not been graded across any dimension yet. Treat the label above as provisional and read the source.
What is missing. This record has no bottom line, key findings, reported figures, evidence dimensions. That is a gap in the analysis, not a judgement about the study.
Registry record from ClinicalTrials.gov (NCT03748446). This is a study registration, not published results. Lead sponsor: Massachusetts General Hospital. Recruitment status: COMPLETED. Phase: EARLY_PHASE1. Study type: INTERVENTIONAL. Enrollment: 13 participants (ACTUAL). Conditions: Major Depressive Disorder, Bipolar Depression. Interventions: DRUG: Xenon; DRUG: Nitrogen gas. Primary outcome measures: Depressive Symptoms , Improvement at day 1; Depressive Symptoms , Improvement at day 1. Brief summary: The investigators will test the hypothesis that inhaled xenon will produce a rapid improvement in depressive symptoms in patients suffering from treatment-resistant depression. Specifically, the investigators will conduct a parallel randomized, double-blind crossover study that will compare the effects of xenon-oxygen (35:65 ratio by volume) added to treatment as usual (X-TAU group) to the effects of nitrogen-oxygen (35:65 ratio by volume) added to treatment as usual (N-TAU group). A total of 20 severely depressed patients, 10 with major depressive disorder (MDD) and 10 with Bipolar Depression (BP), will be exposed in random order to N-TAU and X-TAU in a double-blind protocol.